Novartis: arthritis drug meets goal in late-stage trial
(CercleFinance.com) - Novartis said that its psoriasis drug Cosentyx has met the primary endpoint of a final stage trial for the treatment of patients with axial spondyloarthritis, showing a "significant and clinically meaningful" reduction in disease activity.
The ongoing Phase III trial, - which enrolled 555 male and female adult patients with active non-radiographic axial spondyloarthritis - met its primary endpoint at week 16, taking the treatment one step toward its final marketing approval.
There are approximately 1.7 million patients with non-radiographic axial spondyloarthritis in the EU and US.
The disease entails chronic inflammatory back pain and other symptoms such as nocturnal pain.
Copyright (c) 2019 CercleFinance.com. All rights reserved.